

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2001/0034330	10/25/01	Kensil	514	44	01/12/01
	A2	2003/0148261	08/07/03	Fikrig <i>et al.</i>	435	5	03/11/02
	A3	2003/0162190	08/28/03	Gorenstein <i>et al.</i>	435	6	08/06/02
	A4	2003/0162216	08/28/03	Gold <i>et al.</i>	435	6	02/27/03
	A5	2003/0180329	09/25/03	Monath <i>et al.</i>	424	218.1	01/15/03
	A6	2003/0186906	10/02/03	Schlingensiepen <i>et al.</i>	514	44	10/31/02
	A7	2003/0228327	12/11/03	Lasher <i>et al.</i>	424	188.1	11/04/02
	A8	2004/0037848	02/26/04	Audonnet <i>et al.</i>	424	199.1	02/26/03
	A9	2004/0052818	03/18/04	Heinz <i>et al.</i>	424	202.1	10/23/03
	A10	2005/0002968	01/06/05	Monath <i>et al.</i>	424	218.1	02/27/04
	A11	2005/0031641	02/10/05	Loosmore <i>et al.</i>	424	199.1	10/06/03
	A12	2005/0053624	03/10/05	Arroyo <i>et al.</i>	424	218.1	11/17/03
	A13	2005/0163804	07/28/05	Chang	424	218.1	07/06/04
	A14	2005/0164170	07/28/05	Despres <i>et al.</i>	435	5	10/04/04
	A15	4,447,356	05/08/84	Oliver <i>et al.</i>	530	327	06/04/82
	A16	4,500,512	02/19/85	Barme	424	218.1	05/05/82
	A17	4,810,492	11/19/86	Fujita <i>et al.</i>	424	4186.1	03/07/89
	A18	5,218,088	06/08/93	Gorenstein <i>et al.</i>	536	25.34	11/02/89
	A19	5,220,007	06/15/93	Pederson <i>et al.</i>	536	523.1	02/19/92
	A20	5,270,163	12/14/93	Gold <i>et al.</i>	435	6	08/17/92
	A21	5,284,760	02/08/94	Feinstone <i>et al.</i>	435	491.1	09/23/91
	A22	5,354,670	10/11/94	Nickoloff <i>et al.</i>	435	491.53	08/11/93
	A23	5,366,878	11/22/94	Pederson <i>et al.</i>	435	491.3	03/24/93

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>		Other Art <i>See Page 6-14</i>

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A24	5,389,514	02/14/95	Taylor	435	46	08/28/92
	A25	5,397,698	03/14/95	Goodman <i>et al.</i>	435	6	11/02/93
	A26	5,475,096	12/12/95	Gold <i>et al.</i>	536	23.1	06/10/91
	A27	5,514,774	05/07/96	Olivera <i>et al.</i>	530	324	10/19/93
	A28	5,576,302	11/19/96	Cook <i>et al.</i>	514	44	06/06/95
	A29	5,582,981	12/10/96	Toole <i>et al.</i>	435	6	04/28/94
	A30	5,587,361	12/24/96	Cook <i>et al.</i>	514	44	06/06/95
	A31	5,589,340	12/31/96	Olivera <i>et al.</i>	435	6	06/07/95
	A32	5,591,821	01/07/97	Olivera <i>et al.</i>	530	324	07/16/93
	A33	5,595,972	01/21/97	Olivera <i>et al.</i>	514	13	06/07/95
	A34	5,599,797	02/04/97	Cook <i>et al.</i>	514	44	06/06/95
	A35	5,602,000	02/11/97	Hyman	435	91.1	06/23/95
	A36	5,607,923	03/04/97	Cook <i>et al.</i>	514	44	06/06/95
	A37	5,620,963	04/15/97	Cook <i>et al.</i>	514	44	06/06/95
	A38	5,633,347	05/27/97	Olivera <i>et al.</i>	530	324	06/07/95
	A39	5,635,377	06/03/97	Pederson <i>et al.</i>	435	91.3	11/18/94
	A40	5,635,488	06/03/97	Cook <i>et al.</i>	435	44	06/06/95
	A41	5,639,603	06/17/97	Dower <i>et al.</i>	435	6	11/02/93
	A42	5,639,873	06/17/97	Barascut <i>et al.</i>	536	25.3	08/04/94
	A43	5,660,985	08/26/97	Pieken <i>et al.</i>	435	6	04/27/95
	A44	5,661,134	08/26/97	Cook <i>et al.</i>	514	44	06/06/95
	A45	5,663,153	09/02/97	Hutcherson <i>et al.</i>	514	44	06/06/95
	A46	5,668,265	09/16/97	Nadeau <i>et al.</i>	536	23.1	03/12/96

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A47	5,670,622	09/23/97	Shon <i>et al.</i>	530	324	02/15/96
	A48	5,670,637	09/23/97	Gold <i>et al.</i>	536	22.1	03/27/95
	A49	5,672,682	09/30/97	Terlau <i>et al.</i>	530	324	03/18/96
	A50	5,696,249	12/09/97	Gold <i>et al.</i>	536	23.1	03/24/95
	A51	5,705,337	01/06/98	Gold <i>et al.</i>	435	6	03/08/95
	A52	5,719,264	02/17/98	Shon <i>et al.</i>	530	324	10/07/94
	A53	5,734,041	03/31/98	Just <i>et al.</i>	536	25.31	10/20/95
	A54	5,736,148	04/07/98	Sumiyoshi <i>et al.</i>	424	218.1	05/11/95
	A55	5,739,276	04/14/98	Shon <i>et al.</i>	530	324	03/29/96
	A56	5,744,140	04/28/98	Paoletti <i>et al.</i>	424	4199.1	04/07/94
	A57	5,744,141	04/28/98	Paoletti <i>et al.</i>	424	4199.1	06/07/95
	A58	5,756,291	05/26/98	Griffin <i>et al.</i>	435	6	06/07/95
	A59	5,763,595	06/09/98	Gold <i>et al.</i>	536	22.1	06/05/95
	A60	5,780,221	07/14/98	Schumacher <i>et al.</i>	435	5	03/28/96
	A61	5,789,166	08/04/98	Bauer <i>et al.</i>	435	46	12/08/95
	A62	5,795,721	08/18/98	Rabin <i>et al.</i>	435	6	01/25/96
	A63	5,798,208	08/25/98	Crea	435	46	11/02/92
	A64	5,801,154	09/01/98	Baracchini <i>et al.</i>	514	44	04/08/97
	A65	5,804,445	09/08/98	Brasier	435	375	01/11/96
	A66	5,830,650	11/03/98	Crea	435	6	05/30/95
	A67	5,844,106	12/01/98	Seela <i>et al.</i>	536	22.1	11/06/95
	A68	5,853,984	12/29/98	Davis <i>et al.</i>	435	6	06/07/95
	A69	5,874,219	02/23/99	Rava	435	6	04/09/96

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant Alan Barrett <i>et al.</i>	
	Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A70	5,885,780	03/23/99	Olivera <i>et al.</i>	435	7.1	07/19/91
	A71	5,969,096	10/19/99	Shon <i>et al.</i>	530	325	06/26/98
	A72	5,990,295	11/23/99	Shon <i>et al.</i>	536	23.5	01/13/98
	A73	6,150,088	11/21/00	Chan <i>et al.</i>	435	5	04/17/98
	A74	6,171,792	01/09/01	Brent <i>et al.</i>	435	6	11/10/98
	A75	6,171,854	01/09/01	Galler <i>et al.</i>	435	320.1	04/10/98
	A76	6,180,348	01/30/01	Li	435	6	04/07/99
	A77	6,184,024	02/06/01	Lai <i>et al.</i>	435	235.1	05/27/94
	A78	6,242,246	06/06/01	Gold <i>et al.</i>	435	287.1	12/15/97
	A79	6,254,873	07/03/01	Putnak <i>et al.</i>	424	218.1	04/17/95
	A80	6,265,541	07/24/01	Olivera <i>et al.</i>	530	326	12/23/98
	A81	6,337,073	01/08/02	Niedrig <i>et al.</i>	424	218.1	07/01/99
	A82	6,346,611	02/12/02	Pagratis <i>et al.</i>	536	23.1.	07/29/99
	A83	6,369,208	04/09/02	Cole <i>et al.</i>	536	23.1	03/30/98
	A84	6,372,221	04/16/02	Mannhalter <i>et al.</i>	424	196.11	01/03/97
	A85	6,423,493	07/23/02	Gorenstein <i>et al.</i>	435	6	10/25/99
	A86	6,458,543	10/01/02	Gold <i>et al.</i>	435	6	11/28/00
	A87	6,503,715	01/07/03	Gold <i>et al.</i>	435	6	11/28/00
	A88	6,506,554	01/14/03	Chan <i>et al.</i>	435	5	01/18/00
	A89	6,514,948	02/04/03	Raz <i>et al.</i>	514	44	07/02/99
	A90	6,544,776	04/08/03	Gold <i>et al.</i>	435	287.2	08/14/00
	A91	6,551,795	04/22/03	Rubenfield <i>et al.</i>	435	69.1	02/18/99
	A92	6,576,757	06/10/03	Punnonen <i>et al.</i>	536	23.72	11/28/00

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

**EXAMINER:****DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A93	6,610,504	08/26/03	Yuan	435	15	04/10/00
	A94	6,713,616	03/30/04	Pagratis <i>et al.</i>	536	23.1	02/23/01
	A95	6,716,629	04/06/04	Hess <i>et al.</i>	435	420	10/10/01
	A96	6,725,526	04/27/04	Lille	29	603.1	01/14/02
	A97	6,734,022	05/11/04	Hutchens <i>et al.</i>	436	173	03/15/01
	A98	6,844,165	01/18/05	Hutchens <i>et al.</i>	435	7.92	12/21/00
	A99	6,867,289	03/15/05	Gorenstein <i>et al.</i>	536	23.1	10/25/99

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	WO 01/60847	08/23/01	WIPO	English
	B2	WO 02/072036	09/19/02	WIPO	English
	B3	WO 02/081621	10/17/02	WIPO	English Abstract
	B4	WO 03/048184	06/12/03	WIPO	English
	B5	WO 03/061555	07/31/03	WIPO	English
	B6	WO 03/103571	12/18/03	WIPO	English
	B7	WO 04/016586	02/26/04	WIPO	English
	B8	WO 04/045529	06/03/04	WIPO	English
	B9	WO 05/042014	05/12/05	WIPO	English

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Amarzguioui <i>et al.</i> , "Tolerance for mutations and chemical modification in a siRNA," <i>Nuc. Acids Res.</i> , 31:589-595, 2003.
	C2	Anderson <i>et al.</i> , "A phylogenetic approach to following West Nile virus in Connecticut," <i>PNAS</i> , 98:12885-12889, 2001.
	C3	Arroyo <i>et al.</i> , "ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy," <i>J. Virology</i> , 78:12497-12507, 2004.
	C4	Bane <i>et al.</i> , "DNA affinity capture and protein profiling by SELDI-TOF mass spectrometry: effect of DNA methylation," <i>Nucleic Acids Research</i> , 30:e69, 2002.
	C5	Bartelma <i>et al.</i> , "Expression, Purification, and Characterization of the RNA 5'-Triphosphatase Activity of Dengue Virus Type 2 Nonstructural Protein 3," <i>Virology</i> , 299: 122-132, 2002.
	C6	Beasley and Barrett, "Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein." <i>J. Virol.</i> , 76(24):13097-13100, 2002.
	C7	Beasley <i>et al.</i> , "Limited evolution of West Nile virus has occurred during its southwesterly spread in the United States," <i>Virology</i> , 309: 190-195, 2003.
	C8	Beasley <i>et al.</i> , "Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype." <i>J. Virol.</i> , 296(1):17-23, 2002.
	C9	Berthet <i>et al.</i> , "Extensive nucleotide changes and deletions within the envelope glycoprotein gene of Euro-African West Nile viruses," <i>J. General Virology</i> , 78: 2293-2297, 1997.
	C10	Bhardwaj <i>et al.</i> , "Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein." <i>J. Virol.</i> , 75:4002-4007, 2001.
	C11	Blitvich <i>et al.</i> , "Serologic evidence of West Nile virus infection in horses, Coahuila State, Mexico," <i>Emerg. Infect. Dis.</i> , 9: 853-856, 2003.
	C12	Braasch <i>et al.</i> , "Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design," <i>Nucleic Acids Res.</i> , 30:5150-7, 2002.
	C13	Brinton, "The molecular biology of West Nile Virus: a new invader of the western hemisphere," <i>Annu. Rev. Microbiol.</i> , 56:371-402, 2002.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

25526940.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C14	Brown <i>et al.</i> , "Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?" <i>J. Immunol.</i> , 156(9):3285-3291, 1996.
	C15	Burke and Monath, "Flaviviruses," In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), <i>Fields virology</i> , 4th ed., vol. 1: Lippincott Williams & Wilkins, Philadelphia, Pa., 1043-1125, 2001.
	C16	Burton and Barbas, "Human antibodies from combinatorial libraries." <i>Adv. Immunol.</i> , 57:191-280, 1994.
	C17	Butrapet <i>et al.</i> , "Attenuation Markers of a Candidate Dengue Type 2 Vaccine Virus, Strain 16681 (PDK-53), Are Defined by Mutations in the 5' Noncoding Region and Nonstructural Proteins 1 and 3," <i>J. Virology</i> , 74:3011-3019, 2000.
	C18	Caplen <i>et al.</i> , "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate systems," <i>PNAS</i> , 98:9742-9747, 2001.
	C19	CDC, "Serological and molecular amplification assays for West Nile & other arboviruses," 2001.
	C20	Chambers <i>et al.</i> , "West Nile virus envelope proteins: nucleotide sequence analysis of strains differing in mouse neuroinvasiveness," <i>J. General Virology</i> , 79: 2375-2380, 1998.
	C21	Chappell <i>et al.</i> , "Site-directed Mutagenesis and Kinetic Studies of the West Nile Virus NS3 Protease Identify Key Enzyme-Substrate Interactions," <i>J. Biol. Chem.</i> , 280(4): 2896-2903, 2005.
	C22	Charrel <i>et al.</i> , "Evolutionary relationship between Old World West Nile virus strains Evidence for viral gene flow between Africa, the Middle East, and Europe," <i>Virology</i> , 315: 381-388, 2003
	C23	Chi, "Genomewide view of gene silencing by small interfering RNAs," <i>PNAS</i> , 100:6343-6, 2003.
	C24	Crill and Roehrig, "Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells." <i>J. Virol.</i> , 75(16):7769-7773, 2001.
	C25	Davis <i>et al.</i> , "Genetic variation among temporally and geographically distinct West Nile virus isolates collected in the United States, 2001 and 2002," <i>Emerg. Infect. Dis.</i> , 10(1): 160, 2004.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

25526940.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C26	Dobler <i>et al.</i> , "Diagnosis of tick-borne encephalitis: evaluation of sera with borderline titers with the TBE-ELISA." <i>Infection</i> , 24:405-406, 1996.
	C27	Dunster <i>et al.</i> , "Attenuation of virulence of flaviviruses following passage in HeLa cells," <i>J. Gen. Vir.</i> , 71: 601-607, 1990.
	C28	Dupuis <i>et al.</i> , "Serological evidence of West Nile virus transmission, Jamaica, West Indies," <i>Emerg. Infect. Dis.</i> , 9: 860-863, 2003.
	C29	Ebel <i>et al.</i> , "Genetic and Phenotypic Variation of West Nile Virus in New York, 2000-2003," <i>Am. J. Trop. Med. Hyg.</i> , 71(4): 493-500, 2004.
	C30	Egloff <i>et al.</i> , "An RNA cap (nucleoside-2'-O)-Methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization," <i>The EMBO Journal</i> , 21(11): 2757-2768, 2002.
	C31	Elbashir <i>et al.</i> , "Functional anatomy of siRNAs for medicating efficient RNAi in drosophilla melanogaster embryo lysate," <i>EMBO Journal</i> , 20:6877-6888, 2001.
	C32	Elbashir <i>et al.</i> , "RNA interference is mediated by 21-and 22-nulceotide RNAs," <i>Genes and Development</i> , 15:188-200, 2001.
	C33	Estrada-Franco <i>et al.</i> , "West Nile virus in Mexico: evidence of widespread circulation since July 2002," <i>Emerg. Infect. Dis.</i> , 9: 1604-1607, 2003.
no dates	C34	Fonseca <i>et al.</i> , "Flavivirus type-specific antigens produced from fusions of a portion of the E protein gene with the Escherichia coli trpE gene." <i>Am. J. Trop. Med. Hyg.</i> , 44(5):500-8, 1991.
	<del>C35</del>	<del>GenBank Accession No. AF196835</del>
	<del>C36</del>	<del>GenBank Accession Number NP_041724</del>
	<del>C37</del>	<del>GenBank Accession Number U117066</del>
	<del>C38</del>	<del>GenBank Accession Number U117067</del>
	<del>C39</del>	<del>GenBank Accession Number U21055</del>
	<del>C40</del>	<del>GenBank Accession Number U21056</del>
	<del>C41</del>	<del>GenBank Accession Number X03700</del>
	<del>C42</del>	<del>GenBank Accession Number X15061</del>

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C43	Gould <i>et al.</i> , "Evolution, epidemiology, and dispersal of flaviviruses revealed by molecular phylogenies." <i>Adv Virus Res</i> , 57:71-103, 2001.
	C44	Gritsun <i>et al.</i> , "Nucleotide and deduced amino acid sequence of the envelope gene of the Vasilchenko strain of TBE virus; comparison with other flaviviruses," <i>Virus Res</i> , 27:201-209, 2003.
	C45	Hahn <i>et al.</i> , "Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it." <i>Proc. Natl. Acad. Sci., USA</i> , 84:2019-2023, 1987.
	C46	Hanley <i>et al.</i> , "Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes," <i>J. Virol.</i> , 76: 525-531, 2002.
	C47	Heinz <i>et al.</i> , In: <i>Virus Taxonomy</i> , Regenmortel <i>et al.</i> eds., 7 <sup>th</sup> International Committee for the Taxonomy of Viruses, p 859-878, Academic Press, San Diego, 2000.
	C48	Hilton <i>et al.</i> , "Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor." <i>J. Biol. Chem.</i> , 271(9):4699-4708, 1996.
	C49	Huang <i>et al.</i> , "Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile Virus," <i>J. Virology</i> , 79: 7300-7310, 2005.
	C50	Jackson <i>et al.</i> , "Isolation of Arabidopsis mutants altered in the light-regulation of chalcone synthase gene expression using a transgenic screening approach." <i>Plant J.</i> , 8:369-380, 1995.
	C51	Jayasena, "Aptamers: an emerging class of molecules that rival antibodies in diagnostics," <i>Clinical Chemistry</i> , 45:1628-1650, 1999.
	C52	Jia <i>et al.</i> , "Genetic analysis of West Nile New York 1999 encephalitis virus." <i>Lancet</i> , 354:1971-1972, 1999.
	C53	Jones <i>et al.</i> , "Flavivirus Capsid Is a Dimeric Alpha-Helical Protein," <i>J. Virology</i> , 77: 7143-7149, 2003.
	C54	Kofler <i>et al.</i> , "Mimicking live flavivirus immunization with a noninfectious RNA vaccine," <i>PNAS</i> , 101(7): 1951-1956, 2004.

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C55	Kunsch <i>et al.</i> , "Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation," <i>Molecular and Cellular Biology</i> , 12:4412-4421, 1992.
	C56	Lanciotti and Kerst, "Nucleic Acid Sequence-Based Amplification Assays for Rapid Detection of West Nile and St. Louis Encephalitis Viruses," <i>J. Clinical Microbiology</i> , 39(12): 4506-4513, 2001.
	C57	Lanciotti <i>et al.</i> , "Complete Genome Sequences and Phylogenetic Analysis of West Nile Virus Strains Isolated from the United States, Europe, and the Middle East," <i>Virology</i> , 298: 96-105, 2002.
	C58	Lanciotti <i>et al.</i> , "Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States." <i>Science</i> , 286(5448):2333-2337, 1999.
	C59	Lee <i>et al.</i> , "Common E Protein Determinants for Attenuation of Glycosaminoglycan-Binding Variants of Japanese Encephalitis and West Nile Viruses," <i>J. Virology</i> , 78(15): 8271-8280, 2004.
	C60	Lescar <i>et al.</i> , "The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH," <i>Cell</i> , 105:137-148, 2001.
	C61	Lustig <i>et al.</i> , "A Live Attenuated West Nile Virus Strain as a Potential Veterinary Vaccine," <i>Viral Immunology</i> , 13(4): 401-410, 2000.
	C62	Ma <i>et al.</i> , "Solution structure of dengue virus capsid protein reveals another fold," <i>PNAS</i> , 101(10): 3414-3419, 2004.
	C63	Mandl <i>et al.</i> , "Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site." <i>J. Virol</i> , 74(20):9601-9609, 2000.
	C64	Marshall <i>et al.</i> , "Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytide," <i>PNAS</i> , 89:6265-6269, 1992.
	C65	Martin <i>et al.</i> , "Molecular basis of mitomycin C resistance in streptomyces: structure and function of the MRD protein." <i>Structure</i> , 10:933-942, 2002.
	C66	Mashimo <i>et al.</i> , "A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice," <i>PNAS</i> , 99(17): 11311-11316, 2002
	C67	McMinn, "The molecular basis of virulence of the encephalitogenic flaviviruses," <i>J. General Virology</i> , 78: 2711-2722, 1997.

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C68	Miller <i>et al.</i> , "Allele-specific silencing of dominant disease genes," <i>PNAS</i> , 100:7195-7200, 2003.
	C69	Monath et al., "West Nile Virus Vaccine," <i>Current Drug Targets</i> , 1: 37-50, 2001.
	C70	<i>Morbidity and Mortality Weekly Report</i> , 51(36):805-824, 2002.
	C71	<i>Morbidity and Mortality Weekly Report</i> , 51(38):862-864, , 2002.
	C72	Murgue <i>et al.</i> , "The ecology and epidemiology of West Nile virus in Africa, Europe and Asia." <i>Curr Top Microbiol Immunol</i> , 267:195-221, 2002.
	C73	Murthy et al., "Crystal Structure of Dengue Virus NS3 Protease in Complex with a Bowman-Birk Inhibitor: Implications for Flaviviral Polyprotein Processing and Drug Design," <i>J. Mol. Biol.</i> , 301: 759-767, 2000.
	C74	Murthy et al., "Dengue Virus NS3 Serine Protease," <i>J. Biol. Chem.</i> , 274(9): 5573-5580, 1999.
	C75	Mutebi <i>et al.</i> , "Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa." <i>J. Virol</i> , 75:6999-7008, 2001.
	C76	Nakamaye <i>et al.</i> , "Direct sequencing of polymerase chain reaction amplified DNA fragments through the incorporation of deoxynucleoside alpha-thiotriphosphates," <i>Nucleic Acids Research</i> , 16: 9947-59, 1988.
	C77	Niedrig <i>et al.</i> , "Comparison of six different commercial IgG-ELISA kits for the detection of TBEV-antibodies." <i>J Clinical Virology</i> , 20:179-182, 2001.
	C78	Papin <i>et al.</i> , "SYBR green-based real-time quantitative PCR assay for detection of West Nile Virus circumvents false-negative results due to strain variability," <i>J. Clin. Microbiol.</i> , 42:1511-1518, 2004.
	C79	Pletnev et al., "West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy," <i>PNAS</i> , 99(5): 3036-3041, 2002.
	C80	Quirin et al., "West Nile virus, Guadeloupe," <i>Emerg. Infect. Dis.</i> , 10: 706-708, 2004.
	C81	Rey <i>et al.</i> , "Changes in the dengue virus major envelope protein on passaging and their localization on the three-dimensional structure of the protein." <i>Nature</i> , 375:291-298, 1995.

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C82	Rey <i>et al.</i> , "The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution," <i>Nature</i> , 375:291-298, 1995.
	C83	Ryan <i>et al.</i> , "Virus-encoded proteinases of the <i>Flaviviridae</i> ," <i>J. General Virology</i> , 79: 947-959, 1998
	C84	Sanchez and Ruiz, "A single nucleotide change in the E protein gene of dengue virus 2 Mexican strain affects neurovirulence in mice." <i>J Gen Virol</i> , 77(Pt 10):2541-2545, 1996.
	C85	Sazani <i>et al.</i> , "Nuclear antisense effects of neutral anionic and cationic oligonucleotide analogs," <i>Nucleic Acids Research</i> , 29:3965-3974, 2001.
	C86	Scherret <i>et al.</i> , "Biological significance of glycosylation of the envelope protein of Kunjin virus." <i>Ann NY Acad Sci</i> , 951:361-363, 2001.
	C87	Semizarov <i>et al.</i> , "Specificity of short interfering RNA determined through gene expression signatures," <i>PNAS</i> , 100:6347-52, 2003.
	C88	Short <i>et al.</i> , "Contribution of antibody heavy chain CDR1 to digoxin binding analyzed by random mutagenesis of phage-displayed Fab 26-10," <i>J. Biol. Chem.</i> , 270:28541-50 1995.
	C89	Shrestha <i>et al.</i> , "Infection and Injury of Neurons by West Nile Encephalitis Virus," <i>J. Virology</i> , 77(24): 13203-13213, 2003.
	C90	Smith <i>et al.</i> , "Sensitivity and specificity of photoaptamer probes," <i>Molecular &amp; Cellular Proteomics</i> , 2:11-18, 2003.
	C91	Song <i>et al.</i> , "Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages," <i>J. Virol.</i> , 77:7174-81, 2003.
	C92	Tesh <i>et al.</i> , "Experimental yellow fever virus infection in the Golden Hamster ( <i>Mesocricetus auratus</i> ). I. Virologic, biochemical, and immunologic studies." <i>J. Infect Dis.</i> , 183:1431-1436, 2001.
	C93	Ueda <i>et al.</i> , "Phosphorothioate-containing RNAs show mRNA activity in the prokaryotic translation systems in vitro," <i>Nucleic Acids Research</i> , 19:547-552, 1991.
	C94	van der Meulen <i>et al.</i> , "West Nile virus in the vertebrate world," <i>Arch. Virol.</i> , 150: 637-657, 2005.
	C95	Volk <i>et al.</i> , "Solution Structure and Antibody Binding Studies of the Envelope Protein Domain III from the New York strain of West Nile Virus," <i>JBC Papers in Press</i> , published on June 9, 2004 as Manuscript M402385200.

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C96	Warren <i>et al.</i> , "A rapid screen of active site mutants in glycinamide ribonucleotide transformylase." <i>Biochemistry</i> , 35(27):8855-8862, 1996.
	C97	Whitehead <i>et al.</i> , "A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys," <i>Journal of Virology</i> , 77:1653-1657, 2003.
	C98	Wong <i>et al.</i> , "Directed mutagenesis of the Rhodobacter capsulatus puhA gene and orf 214: pleiotropic effects on photosynthetic reaction center and light-harvesting 1 complexes." <i>J. Bacteriol.</i> , 178(8):2334-2342, 1996.
	C99	Xie <i>et al.</i> , "Mutation in NS5 protein attenuates mouse neurovirulence of yellow fever 17D vaccine virus," <i>J. General Virology</i> , 79: 1895-1899, 1998.
	C100	Yamshchikov <i>et al.</i> , "An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development," <i>Virology</i> , 330: 304-312, 2004.
	C101	Yamshchikov <i>et al.</i> , "An infectious clone of the West Nile flavivirus," <i>Virology</i> , 281: 294-304, 2001.
	C102	Yang <i>et al.</i> , "Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing," <i>Nucleic Acid Research</i> , 30:132-140, 2002.
	C103	Yang <i>et al.</i> , "Immunofluorescence assay and flow-cytometry selection of bead-bound aptamers," <i>Nucleic Acids Research</i> , 31:e54, 2003.
	C104	Yelton <i>et al.</i> , "Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis." <i>J Immunol</i> , 155(4):1994-2004, 1995.
	C105	Yokota <i>et al.</i> , "Inhibition of intracellular hepatitis C virus by synthetic and vector-derived small interfering RNAs," <i>EMBO Rep.</i> , 4:602-608, 2003.
	C106	Yoshii <i>et al.</i> , "Enzyme-linked immunosorbent assay using recombinant antigens expressed in mammalian cells for serodiagnosis of tick-borne encephalitis." <i>J Virol Methods</i> , 108:171-179, 2003.
	C107	Yu <i>et al.</i> , "Solution Structure and Structural Dynamics of Envelope Protein Domain III of Mosquito- and Tick- Borne Flaviviruses," <i>Biochemistry</i> , 43: 9168-9176, 2004.

25526940.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSG:260US	Serial No. 10/524,939
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Alan Barrett <i>et al.</i>	
		Filing Date: March 4, 2008	Group: 1648
U.S. Patent Documents <i>See Page 1-5</i>	Foreign Patent Documents <i>See Page 5</i>	Other Art <i>See Page 6-14</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C108	Zanotto <i>et al.</i> , "An arbovirus cline across the northern hemisphere." <i>Virology</i> , 210:152-159, 1995.
	C109	Zeng <i>et al.</i> , "ATP-binding site of human brain hexokinase as studied by molecular modeling and site-directed mutagenesis." <i>Biochemistry</i> , 35(40):13157-13164, 1996.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SBC/

25526940.1

EXAMINER: /Stacy B. Chen/

DATE CONSIDERED: 03/01/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.